PMID- 29900520
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2191-219X (Print)
IS  - 2191-219X (Electronic)
IS  - 2191-219X (Linking)
VI  - 8
IP  - 1
DP  - 2018 Jun 13
TI  - Evaluation of D-isomers of 4-borono-2-(18)F-fluoro-phenylalanine and 
      O-(11)C-methyl-tyrosine as brain tumor imaging agents: a comparative PET study 
      with their L-isomers in rat brain glioma.
PG  - 47
LID - 10.1186/s13550-018-0404-6 [doi]
LID - 47
AB  - BACKGROUND: The potential of the D-isomerization of 
      4-borono-2-(18)F-fluoro-phenylalanine ((18)F-FBPA) to improve its target tumor to 
      non-target normal brain tissue ratio (TBR) was evaluated in rat brain glioma and 
      compared with those of L- and D-(11)C-methyl-tyrosine ((11)C-CMT). The L- or 
      D-isomer of (18)F-FBPA was injected into rats through the tail vein, and their 
      whole body kinetics and distributions were assessed using the tissue dissection 
      method up to 90 min after the injection. The kinetics of L- and D-(18)F-FBPA or 
      L- and D-(11)C-CMT in the C-6 glioma-inoculated rat brain were measured for 90 or 
      60 min, respectively, using high-resolution animal PET, and their TBRs were 
      assessed. RESULTS: Tissue dissection analyses showed that D-(18)F-FBPA uptake was 
      significantly lower than that of L-(18)F-FBPA in the brain and abdominal organs, 
      except for the kidney and bladder, reflecting the faster elimination rate of 
      D-(18)F-FBPA than L-(18)F-FBPA from the blood to the urinary tract. PET imaging 
      using (18)F-FBPA revealed that although the brain uptake of D-(18)F-FBPA was 
      significantly lower than that of L-(18)F-FBPA, the TBR of the D-isomer improved 
      to 6.93 from 1.45 for the L-isomer. Similar results were obtained with PET 
      imaging using (11)C-CMT with a smaller improvement in TBR to 1.75 for D-(11)C-CMT 
      from 1.33 for L-(11)C-CMT. CONCLUSIONS: The present results indicate that 
      D-(18)F-FBPA is a better brain tumor imaging agent with higher TBR than its 
      original L-isomer and previously reported tyrosine-based PET imaging agents. This 
      improved TBR of D-(18)F-FBPA without any pre-treatments, such as tentative 
      blood-brain barrier disruption using hyperosmotic agents or sonication, suggests 
      that the D-isomerization of BPA results in the more selective accumulation of 
      (10)B in tumor cells that is more effective and less toxic than conventional 
      L-BPA.
FAU - Kanazawa, Masakatsu
AU  - Kanazawa M
FAU - Nishiyama, Shingo
AU  - Nishiyama S
FAU - Hashimoto, Fumio
AU  - Hashimoto F
AD  - Central Research Laboratory, Hamamatsu Photonics K.K., 5000 Hirakuchi, Hamakita, 
      Hamamatsu, Shizuoka, 434-8601, Japan.
FAU - Kakiuchi, Takeharu
AU  - Kakiuchi T
AD  - Central Research Laboratory, Hamamatsu Photonics K.K., 5000 Hirakuchi, Hamakita, 
      Hamamatsu, Shizuoka, 434-8601, Japan.
FAU - Tsukada, Hideo
AU  - Tsukada H
AUID- ORCID: 0000-0002-8574-293X
AD  - Central Research Laboratory, Hamamatsu Photonics K.K., 5000 Hirakuchi, Hamakita, 
      Hamamatsu, Shizuoka, 434-8601, Japan. tsukada@crl.hpk.co.jp.
LA  - eng
PT  - Journal Article
DEP - 20180613
PL  - Germany
TA  - EJNMMI Res
JT  - EJNMMI research
JID - 101560946
PMC - PMC5999598
OTO - NOTNLM
OT  - 11C-CMT
OT  - 18F-FBPA
OT  - Boron neutron capture therapy
OT  - D-isomer
OT  - Glioma
COIS- ETHICS APPROVAL: All applicable international, national, and/or international 
      guidelines for the care and use of animals were followed. Experiments were 
      approved by the Ethical Committee of the Central Research Laboratory, Hamamatsu 
      Photonics K.K. (Approval number HPK-2016-08). COMPETING INTERESTS: The authors 
      declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature 
      remains neutral with regard to jurisdictional claims in published maps and 
      institutional affiliations.
EDAT- 2018/06/15 06:00
MHDA- 2018/06/15 06:01
PMCR- 2018/06/13
CRDT- 2018/06/15 06:00
PHST- 2018/03/15 00:00 [received]
PHST- 2018/06/01 00:00 [accepted]
PHST- 2018/06/15 06:00 [entrez]
PHST- 2018/06/15 06:00 [pubmed]
PHST- 2018/06/15 06:01 [medline]
PHST- 2018/06/13 00:00 [pmc-release]
AID - 10.1186/s13550-018-0404-6 [pii]
AID - 404 [pii]
AID - 10.1186/s13550-018-0404-6 [doi]
PST - epublish
SO  - EJNMMI Res. 2018 Jun 13;8(1):47. doi: 10.1186/s13550-018-0404-6.